Skip to main content
Kent Academic Repository

Vortioxetine as adjunctive therapy in the treatment of schizophrenia

Redaelli, Sofia, Porffy, Lilla, Oloyede, Ebenezer, Dzahini, Olubanke, Lewis, Gabriella, Lobo, Maria, Whiskey, Eromona, Shergill, Sukhi S. (2022) Vortioxetine as adjunctive therapy in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology, 12 . Article Number 2045125322. ISSN 2045-1261. (doi:10.1177/20451253221110014) (KAR id:95816)


Background: The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking. Objectives: Vortioxetine is a novel antidepressant that has been used as adjunctive therapy for the treatment of psychosis; however, its effectiveness in clinical practice is relatively unknown. In this study, we aimed to determine the potential clinical effectiveness and safety and tolerability of vortioxetine in psychosis. Design: This is a non-interventional, retrospective study on the add-on use of vortioxetine in a group of people with schizophrenia-spectrum disorders in a large UK NHS mental health trust. Methods: Clinical effectiveness of vortioxetine was retrospectively assessed through the Clinical Global Impression – Severity (CGI-S) scale at 3 months. Safety and tolerability were evaluated through treatment discontinuation rates at 3, 6, and 12 months, and clinical reasons were evaluated at the primary endpoint of 3 months. Results: Data were available for 40 subjects with a diagnosis of schizophrenia or schizoaffective disorder–prescribed vortioxetine treatment; 30 (75%) remained on treatment at 3 months. At CGI-S assessment, 15 of the 35 evaluated subjects reported at least a 1-point improvement, from 5 at baseline to 4 after 3 months of treatment. Twenty-six (65%) remained on treatment at 1-year follow-up. The main reasons for those discontinuing treatment were inadequate response (10%) and manic switch (7.5%), while one subject refused treatment. Tolerability to treatment was good, and 36 subjects (90%) reported no adverse events specific to vortioxetine treatment. Conclusion: Schizophrenia is a complex illness, and there is insufficient treatment response in many individuals. A significant proportion of whom may require adjunctive treatments depending on the nature of the residual symptoms. Vortioxetine could be a potentially safe and effective option in such people, but further controlled studies are required.

Item Type: Article
DOI/Identification number: 10.1177/20451253221110014
Additional information: ** From Crossref journal articles via Jisc Publications Router ** History: epub 05-07-2022.
Uncontrolled keywords: Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Psychology (miscellaneous)
Subjects: R Medicine
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Funders: NIHR Imperial Biomedical Research Centre (
SWORD Depositor: JISC Publications Router
Depositing User: JISC Publications Router
Date Deposited: 22 Nov 2022 15:08 UTC
Last Modified: 04 Mar 2024 16:37 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.